One-year rotational stability and refractive outcomes of the Acriva BB T UDM 611 toric ıntraocular lens: A prospective study

PURPOSE: To evaluate the 1-year clinical outcomes of the Acriva BB T UDM 611 toric intraocular lens (IOL) following cataract surgery in patients with preoperative corneal astigmatism, focusing on rotational stability, refractive efficacy, visual acuity, contrast sensitivity (CS), and safety. METHODS: This prospective longitudinal study included 39 eyes of 32 patients with age-related cataract and regular corneal astigmatism ≥1.0 diopter who underwent phacoemulsification and toric IOL implantation at a tertiary eye care center. Preoperative and postoperative assessments included uncorrected (UDVA) and corrected distance visual acuity (CDVA), corneal and refractive astigmatism, IOL rotation, decentration, and tilt. The CSV-1000 test was used to measure CS at 2.5 m under photopic, mesopic, and mesopic with glare conditions. Adverse events were recorded. RESULTS: The mean logMAR UDVA improved significantly from 0.95± 0.39 preoperatively to 0.06 ± 0.10 at 1 year (p < 0.001). The refractive cylinder decreased from -2.17 ± 1.75 D to -0.21 ± 0.32 D (p < 0.001). The mean IOL rotation was 1.61° ±2.35°, with 89.7% of eyes within ±5° and all within ±10° of the intended axis. No IOL repositioning was required. No patients reported disturbing visual phenomena, and no vision-threatening complications occurred during the follow-up. CONCLUSIONS: The Acriva BB T UDM 611 toric IOL demonstrated excellent rotational stability, significant refractive accuracy, and favorable safety and CS outcomes at 1 year postoperatively. These results support its efficacy in correcting pre-existing corneal astigmatism in cataract patients.